| |
All patients (n=29) |
Survivors (n=21) |
Deaths (n=8) |
P |
| Women n (%) |
6 (20.7) |
5 (23.8) |
1 (12.5) |
NSa |
| Age, years |
45.5 ± 8.9 |
45.58 ± 8.9 |
45.8 ± 9.6 |
NSb |
| Duration of disease,years |
5.8 ± 3.8 |
6.34 ± 3.94 |
4.52 ± 3.19 |
NSb |
| Diabetesn (%) |
3 (10.3) |
1 (4.8) |
2 (25) |
NSa |
| Systemic hypertension n (%) |
3 (10.3) |
3 (14.3) |
0 (0) |
NSa |
| NTproBNP, pg/mL |
1599.4 ± 847.3 |
1507.3 ± 928.4 |
1758.7 ± 662.9 |
NSb |
| NYHA class (n) |
I–1; II-10; |
I-1; II-9; |
II-1; III-6; |
NSa |
| III–15; IV-3 |
III-9; IV-2 |
IV-1 |
| Serum sodium, mmol/L |
137.2 ± 5.80 |
137.3 ± 5.67 |
137.0 ± 6.58 |
NSb |
| Serum creatinine, mmol/L |
82.88 ± 17.73 |
80.32 ± 18.81 |
89.56 ± 13.28 |
NSb |
| LVEDD, mm |
71.24 ± 8.0 |
70.05 ± 8.50 |
74.75 ± 5.73 |
NSb |
| LVEDV, ml |
230.5 ± 68.5 |
220.2 ± 73.18 |
260.63 ± 48.33 |
NSb |
| LVEF, % |
20.6 ± 8.2 |
22.86 ± 8.83 |
15.13 ± 3.80 |
P<0.05b |
| 6-MWT, m |
454.1 ± 73.1 |
449.5 ± 70.42 |
486.4 ± 66.77 |
NSb |
| mABP, mmHg |
92.26 ± 13.8 |
93.91 ± 15.08 |
88.05 ± 9.01 |
NSb |
| mPAP, mmHg |
42.49 ± 7.27 |
42.07 ± 7.91 |
43.46 ± 5.64 |
NSb |
| TPG, mmHg |
15.14 ± 4.32 |
14.37 ± 4.06 |
17.31 ± 4.44 |
NSb |
| PAWP, mmHg |
27.24 ± 6.31 |
27.57 ± 7.35 |
26.14 ± 6.02 |
NSb |
| PVRI, WU/m2 |
8.1 ± 3.31 |
7.53 ± 3.32 |
9.69 ± 2.71 |
NSb |
| SVRI, WU/m2 |
41.6 ± 10.83 |
41.09 ± 10.50 |
43.42 ± 11.59 |
NSb |
| Vasodilator responder n (%): |
|
|
|
|
| NTP |
20/29 (69.0) |
16/21 (76.2) |
4/8 (50.0) |
NSa |
| NO |
19/29 (65.5) |
17/21 (81.0) |
2/8 (25.0) |
P<0.05a |
| SIL |
18/29 (62.1) |
15/21 (71.4) |
3/8 (37.5) |
NSa |
| SIL/NO |
19/29 (65.5) |
17/21 (81.0) |
2/8 (25.0) |
P<0.05a |
| Data presented are mean ± standard deviation or absolute numbers with percentage for categorical data. aχ2 test, bMann-Whitney U test LVEDD: Left Ventricle End-Diastolic Diameter, LVEDV: Left Ventricle End-Diastolic Volume, LVEF: Left Ventricle Ejection Fraction, mABP: Mean Arterial Blood Pressure, 6-MWT: 6 Minute Walking Test, NO: Nitric Oxide, NTP: Sodium Nitroprusside, PAWP: Pulmonary Capillary Wedge Pressure, PVRI: Pulmonary Vascular Resistance Index, SIL: Sildenafil, SIL/NO:Combination of Oral Sildenafil and Inhaled Nitric Oxide, SVRI: Systemic Vascular Resistance Index, TPG: Transpulmonary Gradient |
|
